What is this summary about?This is a summary of an article originally published in the Multiple Sclerosis Journal. Cladribine tablets (MAVENCLAD (R)) are an oral (taken by mouth) medication, approved for the treatment of people with relapsing forms of multiple sclerosis (MS, with episodes of new or worsening symptoms). They are administered for a maximum of 10 days per year, over a period of 2 years. Cladribine tablets work by temporarily reducing the number of lymphocytes, which are immune cells that help to fight off infections. Because of this, people with MS (also called PwMS) may have concerns about the effect of cladribine tablets on vaccines, as these work via immune cells to build protection against infection.What happened in the MAGNIFY-MS study? A study called MAGNIFY-MS investigated how long it takes for cladribine tablets to begin to work in people with a type of MS called highly active relapsing MS. During the study, some participants received their usual vaccinations against flu (influenza) and against the chickenpox virus (also called varicella zoster virus) as part of their routine medical care. The MAGNIFY-MS study gave the researchers an opportunity to look at how cladribine tablets affect the way the flu and chickenpox virus vaccines work in the body.What were the results? Cladribine tablets do not affect how well the body responds to flu and chickenpox vaccines.What do the results mean? PwMS taking cladribine tablets who are vaccinated against chickenpox, flu or both can be protected against these diseases. An animated video describing this study is also available online. Scan this QR code to watch the video.

Schmierer, K., Wiendl, H., Oreja-Guevara, C., Centonze, D., Chudecka, A., Roy, S., et al. (2023). A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. NEURODEGENERATIVE DISEASE MANAGEMENT, 13(1), 15-21 [10.2217/nmt-2022-0026].

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

Centonze, Diego;
2023-02-01

Abstract

What is this summary about?This is a summary of an article originally published in the Multiple Sclerosis Journal. Cladribine tablets (MAVENCLAD (R)) are an oral (taken by mouth) medication, approved for the treatment of people with relapsing forms of multiple sclerosis (MS, with episodes of new or worsening symptoms). They are administered for a maximum of 10 days per year, over a period of 2 years. Cladribine tablets work by temporarily reducing the number of lymphocytes, which are immune cells that help to fight off infections. Because of this, people with MS (also called PwMS) may have concerns about the effect of cladribine tablets on vaccines, as these work via immune cells to build protection against infection.What happened in the MAGNIFY-MS study? A study called MAGNIFY-MS investigated how long it takes for cladribine tablets to begin to work in people with a type of MS called highly active relapsing MS. During the study, some participants received their usual vaccinations against flu (influenza) and against the chickenpox virus (also called varicella zoster virus) as part of their routine medical care. The MAGNIFY-MS study gave the researchers an opportunity to look at how cladribine tablets affect the way the flu and chickenpox virus vaccines work in the body.What were the results? Cladribine tablets do not affect how well the body responds to flu and chickenpox vaccines.What do the results mean? PwMS taking cladribine tablets who are vaccinated against chickenpox, flu or both can be protected against these diseases. An animated video describing this study is also available online. Scan this QR code to watch the video.
feb-2023
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
chickenpox vaccine
cladribine tablets
flu vaccine
lay summary
multiple sclerosis
plain language summary
Schmierer, K., Wiendl, H., Oreja-Guevara, C., Centonze, D., Chudecka, A., Roy, S., et al. (2023). A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. NEURODEGENERATIVE DISEASE MANAGEMENT, 13(1), 15-21 [10.2217/nmt-2022-0026].
Schmierer, K; Wiendl, H; Oreja-Guevara, C; Centonze, D; Chudecka, A; Roy, S; Boschert, U
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/321846
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact